Salidroside induces cell apoptosis and inhibits the invasiveness of HT29 colorectal cells by regulating protein kinase R, NF-κB and STAT3

Cancer Biomark. 2021;31(1):13-25. doi: 10.3233/CBM-203257.

Abstract

Background: Protein kinase R (PKR) can suppress various types of solid tumors by inducing cellular oxidative stress and apoptosis. Likewise, Slaidorside, a plant flavonoid, was shown to have anti-tumorigenesis in many solid tumors.

Objective: This study evaluated anti-tumorigenesis of Salidroside in HT29 colorectal cancer and investigated if the underlying mechanism involves activation of PKR.

Methods: Control or PKR deficient cells were cultured in DMEM media treated with 100 μM Salidroside and cell survival, apoptosis, and other biochemical-related markers were evaluated.

Results: Salidroside significantly reduced cell survival and proliferation and increased the release of lactate dehydrogenase (LDH) and levels of single-stranded DNA (ssDNA). It also increased the protein levels of caspases 3 and 8. Concomitantly, Salidroside increased the protein level and activity of PKR and increased the expression of its downstream targets, p-eIF2α (Ser51), p53 MAPK, and p53. On the contrary, it inhibited the nuclear activation of STAT-3 and NF-κB p65. In PKR deficient cells, the partial effects of Salidroside on cell survival, proliferation, and apoptotic markers were observed coincided with no effects on the expression of eIF-2α, and JNK, p53, p38 MAPK, and caspase 8 but with a significant decrease in the nuclear activities of STAT3 and NF-κB.

Conclusion: Salidroside suppresses the tumorigenesis of HT29 CRC by increasing activation of eIF-2α and JNK and upregulation of p53, p38 MAPK, and caspase-8 through upregulating and activation of PKR. However, the tumor suppressor effect of Salidroside requires also inhibition of STAT3 and NF-κB in a PKR-independent mechanism.

Keywords: HT29; NF-κB; STAT3; Salidroside; colorectal; eIF-2α; protein kinase R.

MeSH terms

  • Apoptosis / drug effects*
  • Colorectal Neoplasms / drug therapy*
  • Glucosides / pharmacology
  • Glucosides / therapeutic use*
  • HT29 Cells / drug effects*
  • Humans
  • NF-kappa B / metabolism*
  • Phenols / pharmacology
  • Phenols / therapeutic use*
  • Rhodiola / chemistry*
  • STAT3 Transcription Factor / metabolism*
  • eIF-2 Kinase / metabolism*

Substances

  • Glucosides
  • NF-kappa B
  • Phenols
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • EIF2AK2 protein, human
  • eIF-2 Kinase
  • rhodioloside